PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III

To Learn More Call
201-510-0910

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment

Sponsor
MacroGenics

Protocol Number
MacroGenics Inc. CP-MGAH22-04

To Learn More Call
201-510-0910

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
ECOG-ACRIN

Protocol Number
EA1131

To Learn More Call
201-510-0910

Single Patient IND – Compassionate Use Niraparib (MK-4827)

Sponsor
Tesaro

Protocol Number
Tesaro Compassionate Use-Niraparib

To Learn More Call
201-510-0910

An Exercise RCT to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Protocol Number
2016-0162 Pedlar

To Learn More Call
201-510-0910

A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (cT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY

Sponsor
Alliance

Protocol Number
Alliance A011202

To Learn More Call
201-510-0910

A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamis and Efficacy of VT-464 in Patients with Advanced Breast Cancer

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Innocrin

Protocol Number
INO-VT-464-CL-006

To Learn More Call
201-510-0910

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer

Type of Cancer
Breast Oncology

Sponsor
Alliance Foundation Trials

Protocol Number
AFT-58 (PATINA)

To Learn More Call
201-510-0910

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

Sponsor
Alliance Pre-ECOG

Protocol Number
Alliance Foundation AFT-05 PrECOG0109 PALLAS

To Learn More Call
201-510-0910

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)

Type of Cancer
Breast Oncology

Site
Hackensack

Sponsor
Celldex

Protocol Number
CDX011-04

Cancer Diagnosis
Breast

Phase of Trial
Phase III